Check Cap (MBAI) Stock Price
Check Cap Price
The stock trades about 33% above its 52-week low.
Check Cap stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Check Cap over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Check Cap stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Check Cap's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Check Cap Price |
|---|---|
| 9/2/2026 | 6.39 USD |
| 9/1/2026 | 6.56 USD |
| 8/31/2026 | 6.61 USD |
| 8/28/2026 | 6.58 USD |
| 8/27/2026 | 6.57 USD |
| 8/26/2026 | 6.78 USD |
| 8/25/2026 | 8.08 USD |
| 8/24/2026 | 7.97 USD |
| 8/21/2026 | 8.04 USD |
| 8/20/2026 | 8.02 USD |
| 8/19/2026 | 8.47 USD |
| 8/18/2026 | 8.17 USD |
| 8/17/2026 | 8.02 USD |
| 8/14/2026 | 8.72 USD |
| 8/13/2026 | 8.60 USD |
| 8/12/2026 | 8.82 USD |
| 8/11/2026 | 8.82 USD |
| 8/10/2026 | 9.67 USD |
| 8/7/2026 | 10.41 USD |
| 8/6/2026 | 10.55 USD |
| 8/5/2026 | 9.45 USD |
| 8/4/2026 | 8.29 USD |
| 8/3/2026 | 8.34 USD |
| 7/31/2026 | 7.82 USD |
| 7/30/2026 | 7.90 USD |
| 7/29/2026 | 7.57 USD |
| 7/27/2026 | 7.98 USD |
| 7/23/2026 | 8.64 USD |
| 7/22/2026 | 7.45 USD |
| 7/21/2026 | 7.57 USD |
Check Cap Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Check Cap Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|
| – | – | – | – | – | 76.00 | 98.00 |
| – | – | – | – | – | – | 28.95 |
| -17.00 | -20.00 | -19.00 | -25.00 | -2.00 | -1.00 | 6.00 |
| – | – | – | – | – | -1.32 | 6.12 |
| -17.00 | -19.00 | -17.00 | -25.00 | 4.00 | -15.00 | 44.00 |
| – | 11.76 | -10.53 | 47.06 | -116.00 | -475.00 | -393.33 |
| 4.00 | 6.00 | 6.00 | 5.85 | 7.02 | 7.02 | 7.02 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Check Cap generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Check Cap retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Check Cap's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Check Cap has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Check Cap's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Check Cap stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Check Cap Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Check Cap business model & stock analysis
Check Cap SWOT Analysis
Strengths
Check Cap Ltd has a unique and innovative technology that allows for the non-invasive detection of colorectal cancer.
The company has a strong and dedicated team of researchers and scientists who are continuously working on developing and improving their technology.
Check Cap Ltd has successfully conducted clinical trials and has received positive results, demonstrating the effectiveness of their product.
The company has secured patents for their technology, providing them with a competitive advantage and protection of their intellectual property.
Weaknesses
Check Cap Ltd is a relatively new company and may face challenges in establishing itself in a competitive market.
The cost of the technology may be a barrier for widespread adoption, limiting the potential customer base.
The product is still in the development phase and may require further clinical trials and regulatory approvals before it can be commercially available.
The company relies heavily on external funding to support its research and development activities.
Opportunities
The global demand for non-invasive and accurate cancer detection methods is increasing, providing Check Cap Ltd with a significant growth opportunity.
Partnerships with pharmaceutical companies or healthcare organizations can help in accelerating the development and commercialization of the product.
Expanding into new geographic markets can further increase the customer base and revenue potential for Check Cap Ltd.
Advancements in medical technology and increased awareness of the importance of early cancer detection create a favorable market environment for Check Cap Ltd.
Threats
There may be regulatory challenges and requirements that could delay or limit the commercialization of Check Cap Ltd's product.
Competitors with similar technologies or alternative solutions may enter the market and pose a threat to Check Cap Ltd's market share.
The reimbursement landscape and insurance coverage for non-invasive cancer detection methods may impact the adoption of Check Cap Ltd's product.
The unpredictable nature of the healthcare industry and potential changes in healthcare policies can affect market conditions and demand for Check Cap Ltd's technology.
Check Cap Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Check Cap historical P/E ratio, EBIT multiple, and P/S ratio
Check Cap annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Check Cap shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Check Cap stock splits
Check Cap shareholder structure
| % | Name |
|---|---|
0.42823% | |
0.37833% | |
0.27623% | |
0.16126% | |
0.15617% | |
0.12288% |
Check Cap Beneficial Ownership Filings (SEC 13D/G)
Check Cap Executives and Management Board
14 members · avg. age 55 · 36 % women
Mr. Alex Ovadia (60)
Chief Executive Officer
604,972.00 USD
Management
Dr. Yoav Kimchy (60)
Chief Technology Officer · since 2005
Ms. Mira Rosenzweig (51)
Chief Financial Officer
Mr. Boaz Shpigelman (50)
Vice President - Research and Development
Mr. Joshua Belkar (53)
Vice President - Operations
Mr. Israel Hershko (56)
Vice President - Quality Assurance and Regulatory Affairs
Mr. Dan Hilerowitz
Chief Financial Officer
Board of Directors
Mr. Steven Hanley (54)
Chairman of the Board · since 2015
Ms. Clara Ezed (52)
Independent Director
Dr. Mary Jo Gorman (62)
Independent Director
Mr. XiangQian Lin (37)
Independent Director
Mr. Yuval Yanai (69)
Independent Director
Frequently asked questions about Check Cap
The business model of Check Cap Ltd is focused on developing and commercializing an ingestible capsule system for colorectal cancer screenings. This innovative technology, known as the C-Scan, utilizes ultra-low dose X-ray technology to generate 3D images of the colon. By providing a non-invasive and patient-friendly alternative to traditional colonoscopies, Check Cap aims to increase the accessibility and early detection of colorectal cancer. This approach holds great potential in improving global healthcare outcomes and reducing healthcare costs associated with colorectal cancer screenings. As a leader in medical imaging technology, Check Cap Ltd is committed to driving advancements in the field of gastroenterology and revolutionizing cancer diagnostics.
Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.
The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.
Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.
Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.
Check Cap Ltd is primarily present in Israel, the United States, and Europe.
Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.
6 analysts currently rate the Check Cap stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Check Cap to generate revenue of 76.27 M USD and earnings per share of -2.22 USD.
Converted at the current exchange rate, the Check Cap share trades at 5.50 EUR (6.39 USD).
The Check Cap share (MBAI) is listed on 3 stock exchanges, including: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).
Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.
The expected revenue of Check Cap is 76.27 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Check Cap is -15.60 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Check Cap is currently -2.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Check Cap stock.
The price-to-sales ratio (P/S) of Check Cap is currently 0.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Check Cap stock.
The Eulerpool Quality Score for Check Cap is 2/10.
The ISIN of Check Cap is IL0011336851. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Check Cap is A14QUF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Check Cap is MBAI. The ticker symbol is used to trade Check Cap shares on the stock exchange.
Check Cap paid dividends every year for the past 0 years.
Check Cap is assigned to the 'Health' sector.
The dividends of Check Cap are distributed in USD.
Check Cap stock
Check Cap Peer Group
Check Cap Ticker
Check Cap FIGI
All fundamentals and in-depth analysis of Check Cap
Our stock analysis for Check Cap stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Check Cap. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.